UNSPSC 51343111: Lopinavir

This classification denotes a protease inhibitor with the molecular formula C37H48N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2494G1JF75, chemically known as 1(2h)-pyrimidineacetamide, n-((1s,3s,4s)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahyrdo-alpha-1-methylethyl)-2-oxo-, (alphas)- but generally known as lopinavir, which bears US NIH Compound Identifier 92727.

UNSPSC 51343111 Lopinavir is a Commodity code that nominally identifies a specific antiretroviral pharmaceutical product, but recent state and local solicitations show minimal direct activity under this code. The four opportunities present in the source relate to pharmaceutical procurement broadly—naloxone (an opioid antagonist), direct-to-manufacturer prescription programs, emergency medical supplies including pharmaceuticals, and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing alliance—but none explicitly target lopinavir as a line item or primary procurement focus. The code appears to see little discrete activity at the state and local level; agencies procuring antiretroviral medications typically bundle them within broader pharmaceutical supply contracts, cooperative purchasing agreements, or health-system formulary management rather than issuing solicitations for individual drugs by UNSPSC commodity code.

The issuing bodies in the recent block span state health agencies (Texas Health and Human Services Commission), county public health departments (Seminole County, Florida), municipal fire departments (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, with Oregon participation). The geographic spread includes Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (response deadline July 26, 2023), Texas HHS's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026), Tampa's ITB for medical and first aid supplies for the Fire Department (due March 13, 2026, with an estimated contract value of $700,000), and MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026). None of these opportunities names lopinavir explicitly, suggesting the code has no current, directly targeted state and local procurement activity worth tracking for business development purposes.